Alnylam begins Phase III trial of lumasiran in PH1
PH1 is an ultra-rare disease characterised by excessive oxalate production and renal damage. Credit: John Campbell.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more